Results 111 to 120 of about 52,437 (276)
Cancer, Volume 131, Issue 18, 15 September 2025.Abstract Background Immune checkpoint inhibitors (ICIs) in unselected sarcomas yield limited response rates and tumor control. Long‐term responders have however been reported, suggesting a critical challenge in refining patient selection, by identifying reliable predictive factors for response. Methods The authors conducted a multicenter, retrospective
Mina Fazel +13 more
wiley +1 more source
Blood‐based biomarkers in soft tissue sarcoma: Implications for immune checkpoint inhibitor therapy
International Journal of Cancer, Volume 157, Issue 6, Page 1031-1042, 15 September 2025.Abstract Soft tissue sarcoma (STS) is a rare and heterogeneous cancer, comprising approximately 1% of all adult cancers and 7%–15% of all childhood cancers. In the advanced stages, chemotherapy remains the standard‐of‐care, but efficacy is limited, with a response rate of 15%–30%, and responses are often short‐lived, with median progression‐free ...
Brie‐Anne Mannah +2 more
wiley +1 more source
Occurrence of splenic leiomyosarcoma in dog: anatomopathological findings
Medicina Veterinária, 2017 Leiomyosarcoma is a malignant neoplasm with origin in smooth muscles. It can originate in the vessel wall and interstitium of the spleen smooth muscle, which is considered rare. The objective of this study was to describe clinical and anatomopathological
Thaís de Almeida Moreira +6 more
doaj
Leiomyosarcoma of the stomach.A clinical and pathological study [PDF]
, 1960 John Berg, Gordon McNeer
openalex +1 more source
Trabectedin and low-dose radiation therapy in patients with advanced leiomyosarcoma
Therapeutic Advances in Medical OncologyBackground and objectives: Dimensional response is an unmet need in second lines of advanced soft tissue sarcomas (STS). Indeed, the three approved drugs, pazopanib, trabectedin, and eribulin, achieved an overall response rate (ORR) of less than 10 ...
Javier Martin-Broto +16 more
doaj +1 more source